Shire Targets Teva Over Generic Intuniv

Law360, New York (April 26, 2010, 5:53 PM EDT) -- Shire LLC has launched a patent infringement suit against Teva Pharmaceutical Industries Ltd. over its plans to introduce a generic version of attention deficit hyperactivity disorder drug Intuniv.

Shire filed suit Thursday in the U.S. District Court for the District of Delaware, alleging that Teva's abbreviated new drug application for generic Intuniv infringes two patents.

According to the suit, Israel-based Teva sent Shire a letter on March 12 regarding its proposed generic and stating that the drug would not infringe the patents covering Intuniv.

Shire maintains...
To view the full article, register now.